GREY:ATBPF - Post by User
Comment by
muto412on Aug 15, 2021 8:42pm
174 Views
Post# 33708009
RE:RE:RE:Approved for Phase 111 in the US
RE:RE:RE:Approved for Phase 111 in the USYou're right they won't 'genuflect'. However, Dr. Stauffer has experience with the FDA...he has an understanding of the space and can provide solid guidance on FDA procedures.
"Dr. Stauffer practiced frontline medicine for a decade, including eight years as a US Navy general practice physician. He then joined the US Food and Drug Administration (“FDA”) as a Medical Review Officer for anti-inflammatory and analgesic drugs, subsequently being recruited by Abbott Laboratories as Global Medical Director. Over the succeeding years, Dr. Stauffer led clinical operations, regulatory and medical affairs teams at Alpharma and Ikaria, each of which was acquired in $1.6 billion cash transactions. He was also instrumental in guiding the clinical development programs that underpinned equity raises totaling more than $250 million for Cara Therapeutics, a developer of novel chemical entities to treat post-operative pain and chronic itch in Chronic Kidney Disease."